Insmed INC Form 4 insider transactions

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, executed pre-planned transactions on June 10, 2025, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 trading plan.

INSMED's Chief Legal Officer, Michael Alexander Smith, sold 1,879 shares of common stock for $73.5 per share on June 5, 2025, as part of a pre-arranged 10b5-1 trading plan.

INSMED Inc.'s Chief Legal Officer, Michael Alexander Smith, sold 1,448 shares of common stock for $71.5 per share to cover tax withholding obligations and broker fees related to Restricted Stock Unit vesting.

INSMED Inc.'s Chief Medical Officer, Dr. Martina Flammer, sold 1,686 shares of common stock at $71.50 per share on June 3, 2025, to satisfy tax withholding obligations and cover related broker fees.

INSMED Inc.'s Chief Operating Officer, Roger Adsett, sold 1,860 shares of common stock for $71.5 per share to cover tax withholding obligations and broker fees related to vested Restricted Stock Units.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, sold 1,579 shares of common stock on June 3, 2025, primarily to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

INSMED Inc.'s Chief People Strategy Officer, S. Nicole Schaeffer, sold 1,642 shares of common stock at $71.5 per share to satisfy tax withholding obligations and cover related broker fees.

INSMED Inc. Director David W.J. McGirr sold a total of 6,250 shares of common stock in early June 2025, executed under a pre-existing 10b5-1 trading plan.

INSMED Inc.'s Chair and CEO, William Lewis, reported the exercise of stock options and subsequent sales of common stock totaling 12,302 shares, primarily under a pre-arranged Rule 10b5-1 trading plan.

INSMED Inc.'s Chief Legal Officer, Michael Alexander Smith, sold 26,327 shares of common stock for approximately $1.84 million in late May 2025, as part of a pre-established Rule 10b5-1 trading plan.

INSMED Inc. Director Melvin Sharoky, M.D., reported a gift of 200 shares of common stock, reducing his direct holdings while maintaining significant indirect ownership.

Director Melvin Sharoky reports gifting shares of Insmed Inc. common stock and adjustments to beneficial ownership through various trusts and entities.

Director Clarissa Desjardins reports purchasing Insmed Inc. (INSM) stock in two transactions on May 20 and May 21, 2025.

Insmed Inc.'s Chair and CEO, William Lewis, executed multiple sales of common stock on May 20, 2025, under a pre-arranged 10b5-1 trading plan.

Sara Bonstein, CFO of Insmed Inc., reports the acquisition of stock options and restricted stock units (RSUs) in a recent Form 4 filing.

Roger Adsett, Chief Operating Officer of Insmed Inc., reports the acquisition of restricted stock units and stock options.

S. Nicole Schaeffer, Chief People Strategy Officer at Insmed, acquired stock options and restricted stock units (RSUs) on May 15, 2025.

William Lewis, Chair and CEO of Insmed Inc., reports the acquisition of restricted stock units and stock options, along with adjustments to his beneficial ownership.

Chief Medical Officer Martina Flammer reports acquisition and disposal of Insmed Inc. stock and stock options.

Chief Legal Officer Michael Alexander Smith reports the acquisition of restricted stock units and stock options in Insmed Inc.

Director David R. Brennan acquired 5,058 Restricted Stock Units (RSUs) of Insmed Inc. on May 15, 2025.

Director Carol Schafer reports acquisition of 5,058 Restricted Stock Units (RSUs) in Insmed Inc.

Clarissa Desjardins, a director of Insmed Inc., reported the acquisition of 5,058 Restricted Stock Units (RSUs) on May 15, 2025, bringing her total holdings to 67,007 shares.

Director Melvin Sharoky reports the acquisition of 5,058 Restricted Stock Units (RSUs) in Insmed Inc., along with adjustments to beneficial ownership across various entities.

Director Elizabeth M. Anderson reports acquisition of 5,058 Restricted Stock Units (RSUs) in Insmed Inc.

Director David W.J. McGirr acquired 5,058 Restricted Stock Units (RSUs) in Insmed Inc. on May 15, 2025, increasing his total holdings to 103,973 shares.

Director Leo Lee reports acquisition of 5,058 Restricted Stock Units (RSUs) in Insmed Inc.

Chief Legal Officer of Insmed Inc., Michael Smith, sold shares of common stock to cover tax withholding obligations and broker fees related to the vesting of Restricted Stock Units.

Nicole Schaeffer, Chief People Strategy Officer at Insmed Inc., sold shares of common stock to cover tax withholding obligations and broker fees related to the vesting of Restricted Stock Units.

Insmed Inc. CEO William Lewis sold shares of common stock on May 13th and 14th, 2025, to satisfy tax withholding obligations and broker fees related to the vesting of Restricted Stock Units.